WO2002062325A2 - Method of treating conditions related to platelet activity - Google Patents
Method of treating conditions related to platelet activity Download PDFInfo
- Publication number
- WO2002062325A2 WO2002062325A2 PCT/US2002/003372 US0203372W WO02062325A2 WO 2002062325 A2 WO2002062325 A2 WO 2002062325A2 US 0203372 W US0203372 W US 0203372W WO 02062325 A2 WO02062325 A2 WO 02062325A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cgmp
- platelet
- pkg
- group
- activation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
Definitions
- the present invention relates to methods of treating thrombotic and hemostatic conditions related to platelet activity enhanced by the guanosine 3 ' , 5 ' -cyclic monophosphate (cGMP) -dependent protein kinase signaling pathway.
- One aspect of the present invention relates to a method of treating a thrombotic condition by using an active agent that inhibits production of guanosine 3 ',5' -cyclic monophosphate or that inhibits cGMP-dependent protein kinase (protein kinase G, PKG) in platelets.
- Another aspect of the present invention relates to a method of treating a hemostatic condition.
- the hemostatic condition can be treated by administering an active agent that stimulates production of cGMP or that stimulates the function of PKG in platelets.
- integrins are heterodimers that actively participate in platelet activity.
- the heterodimers generally have an and ⁇ subunit .
- the prototype integrin, ⁇ IIb ⁇ 3 on nonactivated platelets circulating in the bloodstream has a low affinity for binding to its ligands, for example fibrinogen.
- platelets At sites of vascular injury, exposure of the platelets to various soluble agonists, such as thrombin and adenosine diphosphate (ADP) , or subendoethelial adhesive proteins, for example collagen and von illebrand factor (vWF) , induces a series of morphological and biochemical changes, i.e., platelet activation. Platelet activation leads to enhanced ligand binding function of integrin ⁇ IIb ⁇ 3 and, accordingly, adhesion and aggregation of the platelets .
- ADP adenosine diphosphate
- vWF von illebrand factor
- the initial platelet adhesion is dependent on the platelet vWF receptor, i.e., the glycoprotein lb-IX complex (GPIb-IX) , which induces signal activating ligand binding function of integrin IIb ⁇ 3 .
- GPIb-IX glycoprotein lb-IX complex
- the important role of integrins in platelet adhesion and aggregation has been linked causally to thrombotic diseases, for example, heart attack, stroke, and hemostasis.
- the function of PKG is stimulated by cGMP .
- nitric oxide NO
- nitroprusside agents that elevate intracellular cGMP and adenosine 3 ',5' -cyclic monophosphate (cAMP) . It has been theorized that elevated levels of cGMP stimulate cGMP-dependent protein kinase production, which inhibits platelet activity.
- sildenafil One active agent, sildenafil, is commercially available from Pfizer, Inc. (New York, New York, U.S.A.) as VIAGRA ® .
- Sildenafil enhances intracellular levels of cGMP by inhibiting phospho- diesterase 5 (PDE5) , an enzyme that hydrolyzes cGMP .
- PDE5 phospho- diesterase 5
- cGMP-enhancing drugs such as sildenafil
- sildenafil are expected to inhibit platelet activation and thereby reduce incidences of thrombosis.
- sildenafil does not inhibit platelet activation.
- an increasing number of clinical reports associate severe thrombotic conditions with the use of sildenafil, which indicates that, unlike nitric oxide and nitroprusside, specific cGMP-enhancing drugs do not inhibit platelet activation.
- cGMP-dependent protein kinase is a family of intracellular signaling enzymes widely distributed in various tissues and cells.
- PKG signaling plays a significant role in the cGMP-PKG pathway, which mediates platelet activation. It is theorized, but not relied upon herein, that PKG catalyzes phosphorylation of several cytoskeletal and signaling molecules useful in cytoskeleton organization, cell migration, secretion and neuron signal transmission, including vasodilator-stimulated phosphoprotein, upon activation by cGMP binding.
- cGMP induces biphasic platelet response.
- cGMP enhances activation of integrin ⁇ IIb ⁇ 3 and integrin-dependent platelet aggregation induced by vWF and thrombin.
- binding of vWF to the platelet vWF receptor induces and enhances cGMP level and activate platelets via the PKG-cRaf-MEK (mitogen-activated protein kinase/- extracellular signal-regulated kinase kinase) -ERK
- an inhibitor of guanylyl cyclase an enzyme useful in cGMP production
- an inhibitor of PKG an activator of cGMP-specific phosphodiesterase
- an enzyme that hydrolyzes cGMP an inhibitor of the cRaf-MEK-ERK pathway, an inhibitor of the p38 path-- way, or mixtures thereof
- thrombotic conditions such as myocardial infarction, cerebral thrombosis, and other arterial thrombosis.
- activators of guanylyl cyclase, activators of PKG, and inhibitors of cGMP-specific phosphodiesterases are administered to a patient to enhance platelet activities for treating hemostatic conditions, such as von illebrand disease and thrombocytopenia.
- Von Willebrand disease can be caused by a decrease in the quantity of vWF (type I) or a decrease in the function of vWF (type IIA) to bind to its platelet receptor, GPIb-IX. It has been found that GPIb-IX induces platelet activation via a PKG-dependent pathway, enhancing PKG function or cGMP levels, which can be used to correct platelet dysfunction caused by a decrease in the quantity or function of vWF. Also, enhanced platelet activation via the PKG pathway can compensate for a decrease in platelet numbers or function in patients with thrombocytopenia or functional platelet disorders.
- the present invention provides a method of treating a thrombotic disease or condition, characterized by the formation, presence, or development of a blood clot in blood vessels.
- the method comprises the step of administering a therapeutically effective amount of an active agent that, directly or indirectly, inhibits production of guanosine 3', 5' -cyclic monophosphate (cGMP) or inhibits the function of PKG and its downstream effectors, cRaf-MEK-ERK pathways, to a mammal in need of such treatment.
- an active agent that, directly or indirectly, inhibits production of guanosine 3', 5' -cyclic monophosphate (cGMP) or inhibits the function of PKG and its downstream effectors, cRaf-MEK-ERK pathways, to a mammal in need of such treatment.
- the active agent is selected from the group consisting of guanylyl cyclase inhibitors, cCMP-dependent phosphodiesterase activators, protein kinase G (cGMP-dependent protein kinase, PKG) inhibitors, and inhibitors of cRAF, MEK1, and ERK1/ERK2.
- the present invention also provides a method of treating ⁇ a hemostatic disease or condition.
- Hemostatic diseases and conditions are characterized by a decreased capacity of a human or animal to control or stop bleeding.
- the method of treating a hemostatic disease or condition comprises the step of administering a therapeutically effective amount of an active agent that stimulates production ' of guanosine 3 ' , 5 ' -cyclic monophosphate or PKG to a mammal in need of such treatment.
- the active agent can be any compound that stimulates production of cGMP, inhibits cGMP-specif- ic phosphodiesterase (e.g., phosphodiesterase 5), or stimulates activity of the PKG-cRaf-MEK-ERF pathway.
- Suitable active agents include, but are not limited to, compounds selected from the group consisting of guanylyl cyclase activators, protein kinase G activators, cGMP-specific phosphodiesterase inhibitors, and stimulators of cRaf, MEK, and ERK1/ERK2.
- Fig. 1A shows effects on CHO cells trans- fected with cDNA encoding PKGl or vector
- Fig. IB contains bar graphs showing PKG activity in PKG-transfected cells
- Fig. IC contains plots showing reconsti- tution of GPIb-IX-mediated activation in CHO cells
- Figs. 2A-C contain bar graphs of tests performed on CHO cells for adhesion under flow
- Figs. 3A-C contain plots and stains showing the effects of PKG inhibitors and activators on platelet aggregation induced by vWF-GPIb-IX interaction;
- Fig. 4 contains bar graphs for cGMP concentration vs. a control and various test reactants
- Figs. 5A and B are plots showing the effects of PKG inhibitors (A) and activators (B) on thrombin-induced platelet aggregation;
- Figs. 6A and B are plots showing the effects of sildenafil on platelet aggregation in the presence of ristocetin (A) and thrombin (B) ;
- Figs. 7A-D are plots showing the time- dependent biphasic effects of cGMP on GPIb-IX-depen- dent platelet aggregation;
- Figs. 8A and B illustrate pathways for cGMP signaling in platelet activation and hemo- stasis .
- the platelet integrin oi IIb ⁇ 3 mediates platelet adhesion and aggregation, and plays critical roles in the development of thrombotic diseases, such as heart attack and stroke.
- the integrin ⁇ f IIb ⁇ 3 On circulating resting platelets, the integrin ⁇ f IIb ⁇ 3 has a low affinity for its ligands.
- soluble platelet agonists e.g., thrombin and ADP
- subendothelial adhesive proteins e.g., collagen and von Willebrand factor (vWF)
- platelet activation which represents a series of morphological and biochemical changes and intracellular signaling events, and is characterized by the activation of ligand binding function of integrin o_ IIb ⁇ 3 (see Refs . 1-3).
- platelet adhesion and activation requires the platelet vWF receptor, i.e., glycoprotein Ib-IX complex (GPIb-IX) .
- GPIb-IX interaction with the subendothelium-bound vWF initiates platelet adhesion and triggers integrin ⁇ IIb ⁇ 3 activation, leading to integrin—dependent stable platelet adhesion and aggregation (see Refs . 4-14).
- GPIblX binds thrombin, and is required for platelet aggre- gation induced by low-dose thrombin (see Refs . 15- 21) .
- GPIb-IX pathway in thrombosis and hemostasis is manifested in an inherited disease, i.e., Bernard—Soulier syndrome, in which genetic deficiency in GPIb-IX causes defects in platelet adhesion and activation, and results in bleeding disorder (see Ref. 22) .
- the signaling pathways of GPIb-IX-mediated integrin activation are not totally clear. It has been found that the extracellular stimuli-responsive kinase (ERK) pathway mediates GPIb-IX-dependent integrin activation, and that cGMP-dependent protein kinase (protein kinase G, PKG) are important in promoting activation of ERK (see Ref. 23) .
- ERK extracellular stimuli-responsive kinase
- cGMP-PKG pathway inhibits platelet activation.
- cGMP is an important intracellular secondary messenger synthesized by guanylyl cyclases . Elevation of intracellular cGMP activates PKG, which catalyzes phosphorylation of several intracellular molecules, and regulates important cellular functions, such as cytoskeleton organization, cell migration, secretion, and neuron signal transmission (see Refs. 24-28).
- PKG signaling One important finding in PKG signaling is that the cGMP-PKG pathway mediates nitric oxide (NO) -induced vascular smooth muscle relaxation (see Refs. 29 and 30) .
- NO nitric oxide
- sildenafil a specific cGMP-enhancing drug, sildenafil (VIAGRA ® ) , has been developed and used to treat erectile dysfunction.
- Sildenafil selectively inhibits phosphodiesterase 5 (PDE5) that hydrolyzes cGMP, and thus enhances intracellular cGMP levels (see Ref. 31) .
- PDE5 phosphodiesterase 5
- the role of cGMP-PKG pathway in platelet activation was controversial in the early literature because increases in platelet cGMP levels had been observed in response to either platelet agonists (thrombin, ADP, or collagen) or inhibitors (NO donors such as sodium nitroprusside) .
- cGMP has biphasic effects on platelets, i.e., an early phase transient stimulatory effect that mediates platelet activation and thus thrombus formation, and a second phase inhibitory effect that desensitizes platelets and serves to limit the size of thrombus.
- treatment includes preventing, lowering, stopping, or reversing the progression or severity of the condition or symptoms being treated.
- treatment includes both medical therapeutic and/or prophylactic administration, as appropriate .
- the condition is a thrombotic condition characterized by the formation, presence, or development of a thrombus, or blood clot.
- a thrombotic condition can include abnormal activation of blood clotting factors, for example increased platelet activation.
- Thrombotic conditions include, for example, myocardial infarction, cerebral thrombosis, arterial thrombosis, and occlusion of blood vessels.
- Active agents suitable for treating thrombotic conditions are compounds that inhibit produc- tion of cGMP.
- suitable active agents for treating thrombotic conditions are, for example, compounds that (1) inhibit production of guanosine 3', 5' -cyclic monophosphate (cGMP) in platelets, including, but not limited to, a guanylyl cyclase inhibitor; (2) stimulate a cGMP-specific phosphodiesterase which hydrolyzes cGMP, including, but not limited to, a phosphodiesterase 5 activator; (3) inhibit activity of protein kinase G; (4) inhibit activity of a Raf, MEK, and ERKs, as well as the p38 pathway; and (5) mixtures of the above compounds.
- cGMP guanosine 3', 5' -cyclic monophosphate
- Compounds that can inhibit cGMP production include, but are not limited to, a guanylyl cyclase inhibitor, a protein kinase G inhibitor, and mixtures thereof .
- guanylyl cyclase inhibitors suitable for the invention include, but are not limited to, Ly83583, methylene blue, NS2028, ODQ, zinc (II) protoporphyrin, and mixtures thereof.
- Suitable protein kinase G inhibitors are KT5823, Rp- cGMP, Rp-8-bromo-cGMP, Rp-8-pCPT-cGMP, and mixtures thereof.
- Inhibitors of the cRaf-MEK-ERK pathway and p38 pathway include, but are not limited to, PD98059, U0125, U0126, ZM336372, and apigenin.
- cRaf inhibitors (N- [5- (dimethylaminobenzamide) -2-methylphenyl] -4- hydroxybenzamide (ZM336372) ;
- MEK inhibitors 2"-amino-3"-methoxyflavone (PD98059) ; 1, 4-diamino-2 , 3-dicyano-l, 4-bis (phenylthio) butadiene (U0125) ; 1, 4-diamino-2, 3-dicyano-l , 4-bis (2-aminophenylthio) - butadiene (U0126) ;
- ERK inhibitor 4 ' , 5, 7-trihydroxyflavone (Apigenin) ;
- p38 MAP kinase inhibitors 4- (4-fluorophenyl) -2- (4-methylsulfinylphenyl) -5- (4- pyridyl) -lH-imidazole (SB203580) ;
- hemostasis is characterized by controlling or stopping bleeding, for example in a surgical procedure or during hemorrhage.
- Hemostatic conditions can be related to a decreased ability of platelets ' to function properly, the lack of platelet activation, or a decrease in platelet count.
- Nonlimiting examples of hemostatic conditions include, but are not limited to, von Willebrand disease, thrombocyto- penia, and the like.
- Active agents suitable for treating hemostatic conditions are compounds that activate the production of cGMP .
- a suitable active agents useful in the method of treating hemostatic diseases and conditions include, but are not limited to, guanylyl cylcase activators, protein kinase G activators, and cGMP-specific phosphodiesterase inhibitors.
- a guanylyl cyclase activator suitable for the invention includes, but is not limited to, an atrial natriuretic peptide, a C-type natriuretic peptide, YC-1 (3- (5 ' -hydroxymethyl-2 ' -furyl) -1- benzylindazole) , or a mixture thereof.
- a suitable protein kinase G activator includes, but is not limited, cGMP, 8-bromo-cGMP, 8-pCPT-cGMP, 8-dibutyl- cGMP, or a mixture thereof.
- a cGMP-specific phosphodiesterase inhibitor suitable for use in the method is selected from the group consisting of sildenafil, E4021, DMPPO, MY5441, zaprinast, and the like. Additional cGMP- specific phosphodiesterase inhibitors are disclosed, for example, in International patent application W096/16644, which is incorporated herein by reference.
- the active agents can include, but are not limited, the following, of which each patent or application is incorporated herein by reference; i) a 5-substituted pyrazolo [4, 3-d]- pyrimidine-7-one as disclosed in European patent application 02011889; ii) a grisoleic acid derivative as disclosed in European patent applications nos .
- Patent 4,060,615 xxi) a 6-heterocyclyl oyrazolo [3,4-d]- pyrimidin-4-one as disclosed in U.S. Patent 5,294,612; xxii) a benzimidazole as disclosed in Japanese patent application 5-222000; or xxiii) a cycloheptimidazole as disclosed in European Journal of Pharmacology, 251, (1994), 1; xxiv) a N-containing heterocycle as disclosed in International patent application W094/22855; xxv) a pyrazolopyrimidine derivative as disclosed in European patent application 0636626; xxvi) a 4-aminopyrimidine derivative as disclosed in European patent application 0640599; xxvii) an imidazoquinazoline derivative as disclosed in International patent application WO95/906648; xxviii) an anthranilic acid derivative as disclosed in International patent application WO95/18097; xxix) a 4-aminoquinazo
- Patent 5,436,233 xxx) a tetracyclic derivative as disclosed in U.S. Patent No. 5,859,006; xxxi) an imidazoquinazoline derivative as disclosed in European patent application 0668280; and xxxii) a quinazoline compound as disclosed in European patent application 0669324.
- the methods of the present invention include the use of any compound class disclosed in the patents and applications listed above as well as the particular individual compounds disclosed therein.
- the methods of the present invention can be accomplished using an active agent as described above, or a physiologically acceptable salt or sol- vate thereof.
- the compound, salt, or solvate can be administered as the neat compound, or as a pharmaceutical composition containing either entity.
- the active agents can be administered by any suitable route, for example by oral, buccal, inhalation, sublingual, ' rectal, vaginal, transure- thral , nasal, topical, percutaneous, i.e., trans- dermal, or parenteral (including intravenous, intramuscular, subcutaneous, and intracoronary) administration.
- Parenteral administration can be accomplished using a needle and syringe, or using a high pressure technique, like POWDERJECTTM .
- the compounds and pharmaceutical formulations thereof include those wherein the active ingredient is administered in an effective amount to achieve its intended purpose. More specifically, a "therapeutically effective amount” means an amount effective to prevent development of, or to alleviate the existing symptoms of, the subject being treated. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
- a “therapeutically effective dose” refers to that amount of the compound that results in achieving the desired effect .
- Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cul- tures or experimental animals, e.g., for determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population) .
- the dose ratio between toxic and therapeutic effects is the therapeutic index, which is expressed as the ratio between LD 50 and ED S0 .
- Compounds which exhibit high therapeutic indices are preferred.
- the data obtained from such data can be used in formulating a range of dosage for use in humans .
- the dosage of such compounds preferably lies within a range of circulating concentrations that include the ED 50 with little or no toxicity.
- the dosage can vary within this range depending upon the dosage form employed, and the route of administration utilized.
- the exact formulation, route of administration, and dosage can be chosen by the individual physician in view of the patient's condition. Dosage amount and interval can be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the therapeutic effects.
- the amount of composition administered is dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration, and the judgment of the prescribing physician.
- oral dosages of a compound of formula (I) generally are about 0.5 to about 1000 mg daily for an average adult patient (70 kg) .
- individual tablets or capsules contain 0.2 to 500 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier, for administration in single or multiple doses, once or several times per day.
- Dosages for intravenous, buccal , or sublingual administration typically are 0.1 to 500 mg per single dose as required.
- the physician determines the actual dosing regimen which is most suitable for an individual patient, and the dosage varies with the age, weight, and response of the particular patient.
- the above dosages are exemplary of the average case, but there can be individual instances in which higher or lower dosages are merited, and such are within the scope of this invention.
- a compound for the method of the invention can be administered alone, but generally is administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice.
- Pharmaceutical compositions for use in accordance with the present invention thus can be formulated in a conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries that facilitate processing of compounds of formula (I) into preparations which can be used pharmaceutically.
- compositions can be manufactured in a conventional manner, e.g., by conventional mixing, dissolving, granulating, dragee-making, emulsifying, encapsulating, entrapping, or lyophilizing processes. Proper formulation is dependent upon the route of administration chosen.
- a therapeutically effective amount of a compound of the present invention is administered orally, the composition typically is in the form of a tablet, capsule, powder, solution, or elixir.
- the composition can additionally contain a solid carrier, such as a gelatin or an adjuvant.
- the tablet, capsule, and powder contain about 5% to about 95% compound of the present invention, and preferably from about 25% to about 90% compound of the present invention.
- a liquid carrier such as water, petroleum, or oils of animal or plant origin can be added.
- the liquid form of the composition can further contain physiological saline solution, dextrose or other saccharide solutions, or glycols.
- the composition When administered in liquid form, ' the composition contains about 0.5% to about 90% by weight of a compound of the present invention, and preferably about 1% to about 50% of a compound of the present invention.
- compositions When a therapeutically effective amount of a compound of the present invention is administered by intravenous, cutaneous, or subcutaneous injection, the composition is in the form of a pyrogen- free, parenterally acceptable aqueous solution.
- parenterally acceptable solutions having due regard to pH, isotonicity, stability, and the like, is within the skill in the art.
- a preferred composition for intravenous, cutaneous, or subcutaneous injection typically contains, in addition to a compound of the present invention, an isotonic vehicle.
- Suitable active agents can be readily combined with pharmaceutically acceptable carriers well-known in the art. Such carriers enable the present compounds to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral inges- tion by a patient to be treated.
- Pharmaceutical preparations for oral use can be obtained by adding the active agent with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- Suitable excipients include, for example, fillers and cellulose preparations. If desired, disintegrating agents can be added.
- the active agents are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant.
- the dosage unit can be determined by providing a valve to deliver a metered amount.
- Capsules and cartridges of, e.g., gelatin, for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- the active agents can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
- Formulations for injection can be presented in unit dosage form, e.g., in ampules or in multidose containers, with an added preservative.
- the compositions can take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing, and/or dispersing agents.
- compositions for parenteral administration include aqueous solutions of the active agent in water-soluble form.
- suspensions of the active agents can be prepared as appropriate oily injection suspensions.
- Suitable lipophilic solvents or vehicles include fatty oils or synthetic fatty acid esters.
- Aqueous injection suspensions can contain substances which increase the viscosity of the suspension.
- the suspension also can contain suitable stabilizers or agents that increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.
- a present composition can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use .
- the active agents also can be formulated in rectal compositions, such as suppositories or retention enemas, e.g., containing conventional suppository bases.
- the compounds also can be formulated as a depot preparation.
- Such long-acting formulations can be administered by implantation (for example, subcutaneously or intramuscularly) or by intramuscular injection.
- the active agents can be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- the active agents can be provided as salts with pharmaceutically compatible counterions.
- Such pharmaceutically acceptable base addition salts are those salts that retain the biological effectiveness and properties of the free acids, and that are obtained by reaction with suitable inorganic or organic bases.
- an active agent can be administered orally, buccally, or sublingually in the form of tablets containing excipients, such as starch or lactose, or in capsules or ovules, either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents.
- excipients such as starch or lactose
- capsules or ovules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents.
- Such liquid preparations can be prepared with pharmaceutically acceptable additives, such as suspending agents.
- a compound also can be injected parenterally, for example, intravenously, intramuscularly, subcutaneously, or intracoronarily .
- the compound is best used in the form of a sterile aqueous solution which can contain other substances, for example, salts, or monosaccharides, such as mannitol or glucose, to make the solution isotonic with blood.
- a sterile aqueous solution which can contain other substances, for example, salts, or monosaccharides, such as mannitol or glucose, to make the solution isotonic with blood.
- the active agent or a nontoxic salt thereof is administered as a suitably acceptable formulation in accordance with normal veterinary practice.
- the veterinarian can readily determine the dosing regimen and route of administration that is most appropriate for a particular animal .
- Human PKG I ⁇ cDNA was cloned by RT-PCR, using human platelet mRNA as templates. Sequence of the human PKG I ⁇ cDNA fragment matches the published sequence. Cloning of human PKG I cDNA was described previously. PKG I ⁇ or I ⁇ in pCDNA3. l/Zeo+ vector was transfected into 123 cells (CHO cells expressing recombinant human CPIb-IX and integrin ⁇ IIb ⁇ 3 using Lipofectamine plus (BRL) . Expression of PKG was assessed by Western blotting with an anti- human PKG I antibody (Calbiochem) .
- kinase activity of the expressed enzymes was measured in cell homogehates using BPDEtide (Calbiochem) as substrate as detailed previously.
- vWF-induced GPIb- IX-mediated activation of integrin ⁇ . IIb ⁇ 3 was examined by flow cytometry analysis of Oregon green-labeled fibrinogen binding to integrin ⁇ IIb ⁇ 3 as described previously. Briefly, cells were detached from tissue culture plate using 0.5 mM EDTA, washed at 4°C and resuspended in modified Tyrode ' s solution.
- CHO cells expressing human platelet receptors were resuspended in modified Tyrode ' s buffer, pH 7.4, containing 1 mg/mi of bovine serum albumin (BSA) (see Ref. 46), and final cell count was 5 x 10 5 /ml.
- BSA bovine serum albumin
- Cell interaction with immobilized vWF under flow conditions was observed in real time under a Nikon inverted microscope equipped with a cooled CCD camera.
- Purified human vWF (10 ⁇ g/ml in 0.1 M NaHC0 3 , pH 8.3) was added to glass microcapillary tubes (inner diameter of 1.33 mm and a length of 7.2 cm) , and incubated at 4°C for 20 h.
- vWF-coated microcapillary tubes then were incubated with 5% BSA. After washing, the cell suspension was aspirated through the tube by a syringe pump (Harvard Apparatus Inc.) at desired shear rates for 1.2 minutes and washed with modified Tyrode ' s buffer for additional 10 minutes at the same shear rates to remove transiently adherent cells.
- the experiments were continuously recorded on videotape using a video cassette recorder (model 9500, Sony) .
- the number of stably adherent cell on immobilized vWF was counted on images obtained at 20 randomly selected positions in the vWF-coated tubes.
- CGS buffer sodium chloride 0.12 M, trisodium citrate 0.0129 M and d-glucose 0.03 M, pH 6.5
- PRP platelet-rich plasma
- vWF-dependent platelet aggregation was induced by addition of ristocetin or botrocetin to PRP.
- Platelets were allowed to adhere and spread on 10 ⁇ g/ml vWF-coated glass chamber slides (Nunc) at 37°C for 1 hour. After three washes, platelets were fixed by adding 4% paraformaldehyde in PBS. Platelets were permeabilized by adding 0.1 M Tris, 0.01 M EGTA, 0.15 M NaCI, 5 mM MgCl 2 , pH 7.4, containing 0.1% Triton X-100, 0.5 mM leupeptin, 1 mM PMSF, and 0.1 mM E64 , and then incubated with 20 ⁇ g/ml of anti-GPIba antibody (anti-Ib ⁇ C) at 22°C for 1 hour.
- anti-Ib ⁇ C anti-GPIba antibody
- Washed platelets (3 x 10 8 /ml) resuspended in 400 ⁇ l Tyrode ' s buffer were stirred at 37°C after addition of control buffer, 1 mg/mi ristocetin alone, 15 pg/mi vWF and 1 mg/mi ristocetin, or 100 ⁇ M glyco-SNPl.
- the reaction was stopped by addition of 400 ⁇ l of ice-cold 12% (w/v) trichloroacetic acid. Samples were mixed and centrifuged at 2000 x g for 15 ruin at 4°C. Supenatant was removed and washed with 5 volumes of water-saturated diethyl ether 4 times, and then lyophilized.
- cGMP levels were measured using a cGMP enzyme immunoassay kit from Amersham-Pharmacia Biotech.
- activation of the platelet integrin o iib ⁇ 3 can be reconstituted in Chinese Hamster Ovary (CHO) cells expressing both recombinant human CPIb-IX and integrin ⁇ _ ⁇ Ib ⁇ 3 (123 cells) (see Ref. 13) .
- binding of vWF to GPIb-IX triggers activation of integrin ⁇ IIb ⁇ 3 , thereby allowing specific binding of fibrinogen (a physiological ligand of integrin ⁇ IIb ⁇ 3 .
- Figure 1 shows that expression of recombinant PKG promotes GPIb-LX-mediated integrin activation.
- Fig. 1A CHO cells expressing GPLb-JX and integrin ⁇ IIb ⁇ 3 (123 cells) were transfected with cDNA encoding PKGI ⁇ or vector. Expression of PKG la in 123 cells was detected by Western blotting with an anti-human PKG I antibody
- PKG- or vector-transfected cells were incubated with Oregon Green-labeled fibrinogen (Fg) (20 ⁇ g/ml) and 1 mg/mi ristocetin (No cGMP) for 30 mm with (+vWF) or without (No vWF) adding 12 ⁇ g/ml vWF. These cells were also incubated with Oregon Green-labeled Fg, ristocetin and 8-bromo-cGMP (+cGMP) with or without adding vWF. Nonspecific binding was estimated by adding RGDS which inhibits fibrinogen binding to integrins (Fg+RGDS) . Cells were analyzed by flow cytometry. Quantitative results from three experiments are expressed as fibrinogen binding indices (total bound fluorescence
- CHO cells expressing comparable levels of recombinant human GPIb-IX and/or integrin ⁇ IIb ⁇ 3 were perfused into vWF- coated capillary tubes at shear rates (800 s" 1 and 1500 s "1 ) similar to that seen in arteries.
- GPJb-JX- expressing cells (lb9 cells) showed only limited transient adhesion or rolling on the vWF surface, but failed to stably adhere to vWF-coated surfaces
- FIG. 2A and 2B The cells expressing integrin a n b & 3 alone (2b3a cells) showed a low-level adhesion at 800 s _1 but almost no adhesion at 1500 s" 1 (Fig. 2A and 2B) .
- PKG Ia-transfected 123 cells showed a markedly enhanced stable cell adhesion to vWF at both shear rates (Fig. 2A and 2B) .
- Stable adhesion of PKG-expressing cells was inhibited by RGDS peptides (an integrin inhibitor) , indicating that PKG-stimulated stable adhesion is integrin-de- pendent (Fig. 2C) .
- integrin-dependent adhesion of PKG-expressing 123 cells to vWF under flow conditions was enhanced by addition of a specific cGMP-enhancing drug sildenafil (Fig. 2C) or 8- bromo-cGMP (not shown) .
- Figure 2 shows that PKG enhances GPLb-IX and integrin-dependent cell adhesion under flow.
- Figs. 2A and B vWF-coated capillary tubes were perfused with equivalent numbers
- vector-transfected 123 cells (123) or 123PKG cells also was perfused into vWF- coated glass capillary tubes as described in Fig. 2A in the absence or presence (+RGDS) of an integrin inhibitor RGDS peptide (4 mM) and in the absence (Control) or presence of cGMP-enhancing drug, sildenafil (5 ⁇ M) .
- Stable adhesion of 123PKG cells were significantly higher than vector-transfected 123 cells with or without sildenafii treatments (in all cases, P ⁇ 0.0001).
- Sildenafil significantly increased stable adhesion of vectortransfected 123 cells or 123PKG cells (in all cases, P ⁇ 0.0001) .
- RGDS inhibited stable adhesion of 123PKG cells with or without treatment of sildenafil, and also inhibited stable adhesion of sildenafil-treated 123 cells (in all cases, P ⁇ 0.0001). The experiments were repeated at least three times.
- PKG is important in GPIb-IX-mediated integrin activation in platelets
- ristocetin-induced vWF binding to GPIb-IX causes reversible agglutination of platelets and activation of integrin ⁇ IIb ⁇ 3 , leading to an integrin- dependent second wave of platelet aggregation (Fig. 3A) .
- a selective inhibitor of PKG i.e., KT5823 (2pM)
- abolished the integrin- dependent second wave of platelet aggregation induced by ristocetin Fig. 3A
- KT5823 The inhibitory effect of KT5823 is expected to be specific because Rp-8-pCPT-cGMP, a competitive inhibitor of cGMP binding to PKG, also inhibited ristocetin-induced second wave of platelet aggregation (Fig. 3A) .
- a PKA inhibitor, KT5720 had no inhibitory effects .
- the PKG inhibitors also inhibited botrocetin-induced platelet aggregation (not shown) .
- membrane-permeable PKG activators 8-bromo-cGMP (Fig. 3B) or 8-pCPT-cGMP (not shown)
- Aktcetin or botrocetin
- KT5823 also inhibited platelet spreading on a vWF-coated surface (Fig. 3C) which requires GPIb-IX-induced integrin activation (see Refs. 7, 13, and 14) .
- Figure 3 shows effects of PKG inhibitors and activators on integrin-dependent platelet aggregation induced by vWF-GPIb-IX interaction.
- platelet rich-plasma PRP
- PKG inhibitors KT5823 (2 pM) or Rp-8pCPT-cGMP 0.2 ⁇ M
- PRP was also incubated with DMSO (vehicle for KT5823) , a PKA inhibitor, KT5720 (2 pM) , or buffer (Control) .
- the vWF modulator, ristocetin was then added to induce vWF-GPIb-IX interaction.
- Ristocetin-induced platelet aggregation was recorded using a platelet aggregometer .
- a subthreshold concentration of ristocetin was added to PRP immediately followed by addition of 8-bromo-cGMP or buffer (Control) .
- PRP also was preincubated with integrin inhibitor RGDS before adding ristocetin and 8-bromo- cGMP.
- vWF induces an increase in platelet cGMP levels
- PKG activity is regulated by intracellular cCMP levels.
- cCMP intracellular cCMP levels.
- ligand binding to GPIb-IX is expected to stimulate an increase in intracellular cCMP levels.
- platelet cCMP following ristocetin-induced vWF binding to GPIb-IX, and vWF-induced increase in cGMP levels was inhibited by anti-GPIba monoclonal antibodies but not control IgG (Fig. 4) .
- the cGMP levels in vWF- stimulated platelets were comparable to that stimulated with glyco-SNAPl, a compound that releases nitric oxide and thus activates PKG) (Fig. 4) .
- FIG. 4 shows a vWF-induced increase in intra-platelet cGMP .
- Washed platelets (3 x 108 /ml) were preincubated at 37°C for 10 mm with buffer, control JgG, a monoclonal antibody against GPIba, AK2. Platelets then were further incubated in a platelet aggregometer for 5 minutes after addition of buffer (Control), 1.25 mg/ml ristocetin only (Risto) , ristocetin plus vWF (vWF) (15 ⁇ g/ml) or glyco-SNAPl (100 ⁇ M) .
- GPIb-IX is required for low-dose thrombin-induced platelet aggregation (see Refs. 18-21) .
- 0.05 units/ml of ⁇ -thrombin was used to induce platelet aggregation.
- platelet aggregation was inhibited by RGDS indicating its dependence on integrin activation.
- SZ2 a monoclonal antibody directed against the thrombin binding region of GPIb a chain (GPIb ⁇ ) (Fig. 5A) , but not by control IgG (not shown) .
- KT5823 (2 ⁇ M) and Rp-8-pCPT-cGMP inhibited platelet aggregation induced by 0.05 units/ml thrombin (Fig. 5A) .
- the membrane-permeable cGMP analog, 8-bromo-cGMP when added to platelets together with a subthreshold concentration (0.02 units/ml) of thrombin, induced platelet aggregation (Fig. 5B) .
- FIG. 5 shows effects of PKG inhibitors and activators on thrombin-induced platelet aggregation.
- Fig. 5A washed platelets were preincubated with 40 pg/mi anti-GPIb ⁇ monoclonal antibody SZ2, integrin inhibitor RGDS, or inhibitors of PKG, KT5823 (2 ⁇ M) or Rp-8pCPT-cGMP (0.2mM) (Calbiochem), for 5 min. Platelets also were preincubated with DMSO (vehicle for KT5823) , KT5720 or buffer (Control) as controls. ⁇ -Thrombin (0.05 units/mi) then was added to induce platelet aggregation.
- Nonspecific JgG and RGES peptides also were examined as additional controls, but had no effect (not shown) .
- a subthreshold dose of thrombin was added to platelets immediately followed by addition of PKG activator 8-bromo-cGMP or buffer (Control) . Shown in the figure are the representative results of at least three experiments .
- sildenafil A commercial drug used for treatment of erectile dysfunction, sildenafil, increases intracellular cGMP and activates PKG. Thus, if PKG stimulates platelet activation, sildenafil is expected to be stimulatory. Indeed, addition of sildenafil to platelets induces platelet aggregation together with subthreshold concentrations of either ristocetin (Fig. 6A) or thrombin (Fig. 6B) . Because sildenafil functions by specifically increasing endogenous cGMP, this result further excludes the possibility of nonspecific effects of exogenous cGMP analogs and supports the conclusion that the cGMP- PKG pathway stimulates platelet (integrin) activation. Furthermore, this result provides direct evidence that sildenafil may potentiate platelet activation.
- Figure 6 shows effects of sildenafil on platelet aggregation.
- Fig. 6A increasing concentrations of sildenafil or control 0.15 M NaCl solution were added to platelet-rich plasma followed by a subthreshold concentration of ristocetin. Platelet aggregation was recorded using a platelet aggregometer .
- Fig. 6B sildenafil or control buffer was added to washed platelets followed by addition of subthreshold doses of thrombin to induce platelet aggregation. It was noted that platelet aggregation occurs in the presence of sildenafil.
- the figure includes the representative results of at least three experiments.
- cGMP induces biphasic platelet responses
- the preincubation time required for cGMP to inhibit platelets was shortened when cGMP concentration was increased.
- the preincubation time was shortened to less than 5 minutes. This is consistent with published data that a prolonged preincubation with cCMP or a high concentration (500-3000 ⁇ M) of cGMP is required to inhibit platelet aggregation.
- the apparently paradoxical effects of cGMP are in fact a biphasic effect associated with the timing and levels of cGMP elevation.
- Figure 7 shows a time-dependent biphasic effects of cGMP on GPLb-IX-depen- dent platelet aggregation.
- PRP was preincubated with 0.1 mM 8-bromo-cGMP for increasing lengths of time at 37°C as indicated.
- the vWF modulator, ristocetin (1.25 mg/ml) then was added to induce platelet aggregation in a turbidometric platelet aggregometer.
- Fig. 7B PRP was preincubated with a high concentration of 8-bromo-cGMP (1 mM) for 5 minutes. Ristocetin then was added to induce platelet aggregation.
- Figs. 7A PRP was preincubated with 0.1 mM 8-bromo-cGMP for increasing lengths of time at 37°C as indicated.
- the vWF modulator, ristocetin (1.25 mg/ml) then was added to induce platelet aggregation in
- FIG. 8 illustrates a new concept of cGMP signaling in platelet activation and hemostasis.
- GPIb-IX and other agonists induces elevation of cGMP and activation of PKG which mediates initial phase integrin activation signal via the ERK pathway (see Ref. 23) .
- cGMP induces a second phase negative regulatory signal potentially via several pathways: (1) PKG- mediated TXA2 receptor phosphorylation, (2) VASP phosphorylation, and (3) activation of the PKA pathway (see Refs. 27, 35, 36, 57, and 58) .
- Fig. 8B upon vascular injury, platelets adhere to the exposed subendothelial matrix via GPIb-IX interaction with vWF. This interaction also induces cGMP elevation, which promotes platelet activation and formation of hemostatic thrombi. Platelet activation can also be induced by other agonists such as collagen, thrombin and ADP . Continued cGMP elevation in aggregated platelets induces second phase inhibitory cGMP signaling resulting in inhibition of further recruitment of platelets from blood flow. This prevents overgrowth of hemostatic thrombi (see Ref. 56), thus reducing the probability of thrombosis in normal person. However, in patients at high thrombotic risk, initial phase of cGMP-promoted thrombus formation may be sufficient to cause occlusion of blood vessels leading to thrombosis.
- low dose thrombin requires both GPIb-IX and hepatohelical receptor-coupled signaling pathways
- collagen stimulates both glycoprotein VI and integrin o_2 ⁇ l
- ADP requires both Gi- and Gq- coupled receptor pathways in order to be sufficient to activate platelets.
- cGMP concentration the lower the cGMP concentration, the longer the preincubation time (5 minutes preincubation when using high concentrations (0.5-2 mM) of cGMP analogs, or 15-30 minutes preincubation when using lower concentrations of cGMP (0.1-0.5 mM) (see Refs. 50 and 51). Also, cGMP-induced platelet inhibition requires a longer period of preincubation than high concentrations of NO donors, suggesting that the inhibitory effects of NO donors may involve either a higher peak of cCMP elevation or other mechanisms in addition to cGMP elevation.
- N0- induced platelet inhibition The possible involvement of a different mechanism in N0- induced platelet inhibition is supported by the finding that NO-induced platelet inhibition is reversed by PKA inhibitors, and that some NO donors may have direct negative effect on integrin function (see Refs. 35-37) .
- cGMP induces biphasic platelet responses is important not only to the understanding of the platelet physiology, but also important to pharmacology and therapeutic applications of the cGMP enhancing drugs.
- the specific cGMP-enhancing drug, sildenafil increases intracellular cGMP levels by inhibiting PDE5, and thus causes vasodilation.
- PDE5 is a major phosphodiesterase in platelets (see Ref. 24) .
- sildenafil should inhibit platelet function in a way similar to NO donors.
- sildenafil did not inhibit platelet aggregation in vitro (not shown) , which is consistent with the previous report that sildenafil by itself did not inhibit platelet activation induced by any tested agonists (ADP, collagen, A23 187, U46619, and platelet activating factor) (see Ref. 38) .
- any tested agonists ADP, collagen, A23 187, U46619, and platelet activating factor
- use of sildenafil has been reportedly associated with severe thrombotic events (myocardial infarction and cerebral thrombosis) in some patients, which cannot be satisfactorily explained by the current concept of cGMP signaling (see Refs. 39-42).
- sildenafil by itself is not sufficient to cause platelet activation, this drug enhances platelet activation in the presence of subthreshold concentrations of platelet agonists such as thrombin and vWF that are likely to be present at sites of vascular injury or atherosclerotic lesions.
- platelet agonists such as thrombin and vWF that are likely to be present at sites of vascular injury or atherosclerotic lesions.
- sildenafil potentially may increase thrombotic risks in patients with preexisting thrombotic conditions such as artherosclerosis . This provides a mechanistic reason for caution when prescribing sidenafil or other specific cGMP-enhanc- ing drugs to patients at thrombotic risk.
- Ward CM Andrews RK, Smith AL, Berndt MC: Mocarhagin, a novel cobra venom metallopro- teinase, cleaves the platelet von Willebrand factor receptor glycoprotein Lbalpha. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein lbalpha as a binding site for von Willebrand factor and alpha-thrombin. Biochemistry 35:4929-4938, 1996
- Li Z, Xi X, Du X A mitogen-activated protein kinase-dependent signaling pathway in the activation of platelet integrin ⁇ ilb ⁇ 3 J Biol Chem 276(45) :42226-42232, 2001
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002240259A AU2002240259A1 (en) | 2001-02-08 | 2002-02-05 | Method of treating conditions related to platelet activity |
US10/467,387 US20040087539A1 (en) | 2002-02-05 | 2002-02-05 | Method of treating conditions related to platelet activity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26732601P | 2001-02-08 | 2001-02-08 | |
US60/267,326 | 2001-02-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002062325A2 true WO2002062325A2 (en) | 2002-08-15 |
WO2002062325A8 WO2002062325A8 (en) | 2002-10-24 |
Family
ID=23018314
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/003372 WO2002062325A2 (en) | 2001-02-08 | 2002-02-05 | Method of treating conditions related to platelet activity |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002240259A1 (en) |
WO (1) | WO2002062325A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7935814B2 (en) | 2005-02-28 | 2011-05-03 | Kumamoto University | Nitroguanosine-3′ 5′-cyclic monophosphate compound and protein kinase G activating agent |
-
2002
- 2002-02-05 WO PCT/US2002/003372 patent/WO2002062325A2/en not_active Application Discontinuation
- 2002-02-05 AU AU2002240259A patent/AU2002240259A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
No Search * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7935814B2 (en) | 2005-02-28 | 2011-05-03 | Kumamoto University | Nitroguanosine-3′ 5′-cyclic monophosphate compound and protein kinase G activating agent |
Also Published As
Publication number | Publication date |
---|---|
AU2002240259A1 (en) | 2002-08-19 |
WO2002062325A8 (en) | 2002-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | A stimulatory role for cGMP-dependent protein kinase in platelet activation | |
Detmers et al. | Role of stress-activated mitogen-activated protein kinase (p38) in β2-integrin-dependent neutrophil adhesion and the adhesion-dependent oxidative burst | |
Du | Signaling and regulation of the platelet glycoprotein Ib–IX–V complex | |
Chun et al. | A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya) | |
US9259399B2 (en) | Targeting CDK4 and CDK6 in cancer therapy | |
US10195204B2 (en) | Methods of treating hemoglobinopathies | |
UA125216C2 (en) | Combination therapies | |
Vessey et al. | Pannexin-I/P2X 7 purinergic receptor channels mediate the release of cardioprotectants induced by ischemic pre-and postconditioning | |
CN1977842A (en) | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents | |
Berna-Erro et al. | Regulation of platelet function by Orai, STIM and TRP | |
Zhu et al. | Targeting the phosphatidylinositol 3-kinase/AKT pathway for the treatment of multiple myeloma | |
Juarez et al. | Interaction of interleukin-7 and interleukin-3 with the CXCL12-induced proliferation of B-cell progenitor acute lymphoblastic leukemia | |
TW201806600A (en) | Combination of a BCL-2 inhibitor and a MCL1 inhibitor, uses and pharmaceutical compositions thereof | |
Packham et al. | Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective | |
Durand et al. | The Rap GTPases mediate CXCL13‐and sphingosine1‐phosphate‐induced chemotaxis, adhesion, and Pyk2 tyrosine phosphorylation in B lymphocytes | |
US9687486B2 (en) | Methods of treating atherosclerosis or myeloproliferative neoplasms by administering a lyn kinase activator | |
Mounika et al. | An overview of CDK enzyme inhibitors in cancer therapy | |
KR102000367B1 (en) | PAR1 enhancer and composition for treating wounds including the same | |
US20040087539A1 (en) | Method of treating conditions related to platelet activity | |
US20040038882A1 (en) | Sgk2 and sgk3 used as diagnostic and therapeutic targets | |
WO2002062325A2 (en) | Method of treating conditions related to platelet activity | |
Mouthon et al. | Single administration of thrombopoietin to lethally irradiated mice prevents infectious and thrombotic events leading to mortality | |
Kansra et al. | Src family kinase inhibitors block amphiregulin-mediated autocrine ErbB signaling in normal human keratinocytes | |
RU2415672C2 (en) | Pyrimidylaminobenzamide derivatives for treatment of hyper-eosinophilia | |
US20140271606A1 (en) | Methods of using adenosine receptor antagonists for treating bleeding disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
D17 | Declaration under article 17(2)a | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10467387 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase in: |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |